Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Novel PD-1 inhibitor and application thereof

A PD-1 and inhibitor technology, which is applied in the direction of anti-inflammatory agents, non-central analgesics, medical preparations containing active ingredients, etc., can solve the problems of easy immunogenicity and high production costs

Pending Publication Date: 2018-11-02
EAST CHINA UNIV OF SCI & TECH
View PDF9 Cites 24 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, these macromolecular antibody drugs have disadvantages such as high production costs and easy immunogenicity.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Novel PD-1 inhibitor and application thereof
  • Novel PD-1 inhibitor and application thereof
  • Novel PD-1 inhibitor and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0163] Example 1. Human PD-1 expression vector construction

[0164] According to relevant literature, the target gene was selected as the 34-150 amino acids of human PD-1. The target gene was cloned into the pET-28a vector using NCoI and NdeI restriction sites. Firstly, specific primers were designed according to the two restriction sites of NCoI and NdeI to amplify the human PD-1 gene by PCR. Then use the traditional cloning method to double digest the carrier plasmid and PCR product with two restriction enzymes NCoI and NdeI respectively, then connect them under the action of T4 ligase to form a recombinant plasmid, and finally transform the recombinant plasmid into the large intestine Bacillus DH5α competent cells. Single clones were picked for identification after overnight culture.

Embodiment 2

[0165] Example 2. Expression and purification of human PD-1 protein

[0166] Select the bacterial liquid with a completely matching sequence after the company's sequencing and culture it overnight, extract the plasmid, and then transform the plasmid into the expression host E.coli BL21(DE3) for expression. A single clone transformed into E.coli BL21(DE3) was picked, placed in 20 mL of 2×YT medium containing kanamycin, and cultured in a shaker at 37° C. overnight. The next day, the small culture products were transferred to TB medium containing kanamycin, cultured at 37°C until the OD600 was 0.6-0.8, and induced by adding 0.5mM IPTG at 37°C for 5-7h. Collect bacteria by centrifugation at 4000rpm, lyse Escherichia coli with lysis buffer (50mM Tris-HCl, pH 8.0, 50mM NaCl, 1mM DTT, 0.5mMEDTA, 5% glycerol), then high-pressure crush, centrifuge at 12000rpm for 60min, take precipitation. Wash with washing buffer (20 mM Tris-HCl, pH 8.0, 2M urea, 2.5% Triton X-100) three times, and ...

Embodiment 3

[0167] Example 3. Identification of human PD-1 protein

[0168] The purified human PD-1 protein was subjected to 14% SDS-PAGE gel electrophoresis, and then transferred to a membrane. The transfer current was set to 300mA, and the transfer time was 45min. The membrane was then blocked with 5% skim milk powder for 2 h at room temperature. After removal, incubate overnight at 4°C with mouse anti-human PD-1 monoclonal antibody, rinse three times in 1×TBST solution, incubate with goat anti-mouse monoclonal antibody at room temperature for 2 hours, and rinse three times in 1×TBST solution. After adding the developing solution, develop under the automatic chemiluminescence image analysis system. The results are shown in 2, there is a protein band between 10-15kDa, and it can be visualized under the PD-1 antibody, thus indicating that the purified protein is indeed human PD-1 protein.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to a steroidal derivative as a PD-1 blocker and application thereof, in particular to a compound shown as a formula I below, a medicinal composition containing the compound shownas the formula I below, and application of the compound to treatment of PD-1 mediated related diseases and preparation of medicines for treating the PD-1 mediated related diseases.

Description

technical field [0001] The invention relates to the field of medicinal chemistry; specifically, the invention relates to steroid derivatives targeting hPD-1 protein and applications thereof. Background technique [0002] As we all know, the human body has a powerful and complex immune system, which can resist invading bacteria and viruses externally, remove damaged and aging cells internally, and even monitor mutated cells. The immune system is mainly divided into antigen presenting cells (APC) and T cells. APCs can process and present antigens, T cells receive the specific antigen signal presented by APCs, and then continue to proliferate and activate under the action of co-stimulatory molecules on the surface of APCs. The activation of T cells requires not only the stimulation of the first signal provided by APC, but also the stimulation of the second signal provided by co-stimulatory molecules. These co-stimulatory molecules not only provide co-stimulatory signals to en...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C07J1/00C07J9/00C07J5/00C07J3/00C07J7/00C07J21/00C07J71/00C07J17/00C07J43/00C07J53/00A61K31/566A61K31/565A61K31/567A61K31/5685A61K31/569A61K31/568A61K31/57A61K31/573A61K31/58A61K31/585A61K31/56A61K31/575A61P35/00A61P31/00A61P29/00
CPCC07J1/0011C07J1/0018C07J1/0025C07J1/0037C07J1/0048C07J1/0059C07J1/0066C07J1/0096C07J3/005C07J5/0023C07J5/0053C07J5/0061C07J5/0076C07J7/0005C07J7/002C07J7/0045C07J7/0085C07J9/00C07J9/005C07J17/00C07J21/003C07J43/003C07J53/004C07J53/008C07J71/001C07J71/0031Y02A50/30
Inventor 李洪林朱丽丽王霞全丽娜刁妍妍
Owner EAST CHINA UNIV OF SCI & TECH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com